Discontinue use if urinary retention develops. Patients w/ lower urinary tract obstructive disease including benign prostatic hyperplasia; severe cardiac disease. Monitor patients w/ bladder outlet obstruction & taking muscarinic antagonists. Perform urinalysis & confirm clinical symptoms prior to use. Co-administration w/ CYP3A4 & P-gp inhibitors/inducers; digoxin. Not recommended in eGFR <30 mL/min/1.73 m
2 on dialysis & eGFR <15 mL/min/1.73 m
2 w/ or w/o hemodialysis. Severe hepatic impairment. Pregnancy & lactation. Childn. Elderly.